August 29, 2018 comslyndra

Media

Media & events

Linkedin Twitter Envelope

News

Lyndra Therapeutics Takes on Opioid Use Disorder with Long-Acting Oral Dosage Form

April 9, 2019
Lyndra Therapeutics Takes on Opioid Use Disorder with Long-Acting Oral Dosage Form NIH Grant Fuels Development of Once-Weekly Oral Buprenorphine...
Read More

FUJIFILM Joins Lyndra Therapeutics’ Series B Raise, Bringing Total Round to $60 Million

February 11, 2019
Lyndra Therapeutics announced that FUJIFILM has joined the company’s Series B raise, bringing the total round to $60 million Thanks...
Read More

Lyndra Therapeutics Raises $55 Million in Series B Financing

January 29, 2019
Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, today announced it has raised $55...
Read More
1 2 3 4

publications

  • A pharmaceutical answer to non-adherence: Once weekly oral memantine for Alzheimer’s disease
    A pharmaceutical answer to non-adherence: Once weekly oral memantine for Alzheimer’s disease
  • Changing the Pill: Developments Toward the Promise of an Ultra-Long-Acting Gastroretentive Dosage Form
    Changing the Pill: Developments Toward the Promise of an Ultra-Long-Acting Gastroretentive Dosage Form
  • Development of an Oral Once-Weekly Drug Delivery System for HIV Antiretroviral Therapy
    Development of an Oral Once-Weekly Drug Delivery System for HIV Antiretroviral Therapy
1 2
200px-Elsevier.svg
200px-Elsevier.svg
A pharmaceutical answer to non-adherence: Once weekly oral memantine for Alzheimer’s disease

Rosemary Kanasty, Susan Low, Nupura Bhise, JungYanga, ErickPeeke, MarleneSchwarz, JimWright, BennettCarter, SaumyaMoorthy, TylerGrant, BenDeBenedictis, MeganBishoff, CraigSimses,  Andrew M.Bellinger

URL : View Project
Expert Opinion
Expert Opinion
Changing the Pill: Developments Toward the Promise of an Ultra-Long-Acting Gastroretentive Dosage Form
Journal,  Expert Opinion on Drug Delivery ,  Volume 15, 2018 – Issue 12

Changing the pill: developments toward the promise of an ultra-long-acting gastroretentive dosage form

David H. Altreuter,Ameya R. Kirtane,Tyler Grant,Cecilia Kruger,Giovanni Traverso ORCID Icon &Andrew M. Bellinger
Pages 1189-1198 | Received 17 Jun 2018, Accepted 01 Nov 2018, Accepted author version posted online: 05 Nov 2018, Published online: 13 Nov 2018
URL : View Project
nature-communications
nature-communications
Development of an Oral Once-Weekly Drug Delivery System for HIV Antiretroviral Therapy

Article | OPEN | Published: 

Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy

Ameya R. Kirtane, Omar Abouzid, Daniel Minahan, Taylor Bensel, Alison L. Hill, Christian Selinger, Anna Bershteyn, Morgan Craig, Shirley S. Mo, Hormoz Mazdiyasni, Cody Cleveland, Jaimie Rogner, Young-Ah Lucy Lee, Lucas Booth, Farhad Javid, Sarah J. Wu, Tyler Grant, Andrew M. Bellinger, Boris Nikolic, Alison Hayward, Lowell Wood, Philip A. Eckhoff, Martin A. Nowak, Robert Langer & Giovanni Traverso

Nature Communications  9, Article number: 2 (2018) | Download Citation

URL : View Project

Press Coverage

A Gates Foundation-Backed Startup Wants to Make Daily Pills a Thing of the Past
Business Insider
Read More
Watertown biotech plans first clinical trial of weeklong schizophrenia drug
BBJ
Read More
Lyndra Announces Feasibility Study of Oral Once-Weekly HIV Drug
MD Magazine
Read More
Swallowing A ‘Mini-Pillbox’ Could Change The Way HIV Drugs Are Delivered
NPR
Read More
Drug Capsule May Allow Weekly HIV Treatment
European Pharmaceutical Review
Read More
Once-a-Week Pill for HIV
BBC
Read More
1 2 3